📎 Click on me to view the list of attachments Theme: Deep Indigo Pink & Purple Slate Tech Dark Cyan A Century of Selling Chemistry: Pharmaceutical Advertising, 1885–1970s A curated collection tracing how the same rhetorical playbook — name the problem, sell the solution — persisted across a hundred years of drug marketing, from unregulated Victorian tonics to "syndrome"-branded tranquilizers. 1885 — Cocaine Toothache Drops Lloyd Manufacturing Co., Albany NY Marketed directly to parents for children's dental pain, sold by any druggist, no prescription required. This predates virtually all US drug regulation — the Pure Food and Drug Act (1906) and Harrison Act (1914) were both decades away. The cheerful children's-illustration style does a lot of work normalising an unregulated narcotic as a household remedy.
1901 — Heroin-Hydrochloride Bayer Pharmaceutical Products The famous one. Marketed as a cough suppressant for bronchitis, phthisis, and whooping cough, pitched as cheaper and more efficient than competing remedies, dosed in grains. Bayer trademarked "Heroin" as a brand name before addiction data forced reformulation and eventual withdrawal from that indication.
c.1940 — "Stay Fit and Slim" (Amphetamine Sulphate) Publisher unattributed / repro via The Advertising Archives Pitches amphetamine sulphate as a slimming aid enabling women to "slim while you do the housework." The stated dose — "a couple of grammes daily" — is wildly implausible: therapeutic doses of the era (Benzedrine tablets) were 5–10mg, meaning this figure is roughly 100–200x a normal dose. Likely either advertising hyperbole, a grains/grammes transcription error (2 grains ≈ 130mg would be far more plausible), or an inaccuracy introduced in a later reproduction/recreation of the original ad.
1950s — "Why is this woman tired?" (Dexedrine) Smith, Kline & French Laboratories Pitched to physicians, not patients: distinguishes physical tiredness (treat with rest) from mental/emotional fatigue in "housewives... crushed under a load of dull, routine duties," for which Dexedrine is offered as the remedy. An early instance of medicalising domestic drudgery — a direct forerunner of the "mother's little helper" marketing later associated with benzodiazepines.
c.1950s-60s — "To Brighten the Outlook in Menstrual Dysfunction" (Dexedrine Sulfate) Smith, Kline & French Laboratories Reframes normal menstrual mood and energy fluctuation as "depressive symptoms" and "psychogenic fatigue" requiring a CNS stimulant. Dose stated (5mg) is consistent with genuine therapeutic dosing of the period — unlike the "Stay Fit and Slim" ad, this one is internally plausible as real clinical/trade advertising.
1960s — "Drug Evaders" (Thorazine / Stelazine / Compazine Concentrate) Smith Kline & French Laboratories Institutional advertising aimed squarely at medication compliance anxiety: patients "notoriously" cheek or dispose of tablets, so liquid concentrate is sold as harder to evade. Frames the patient as an adversary to be out-manoeuvred rather than a person being treated.
1960s — "They come around three or four times a day and try to poison me..." (Stelazine Concentrate) Smith Kline & French Laboratories Widely cited as one of the most tone-deaf pharmaceutical ads ever run. The hooded figures are Spanish Nazareno Holy Week penitential robes, not Ku Klux Klan regalia — but the visual is close enough to Klan imagery that the ad has been criticised for decades on that basis regardless of the original intent. Copy pairs a patient's paranoid ideation with genuinely menacing imagery, framing the fear itself as pathology while selling concentrate as a compliance tool for "insuring the medication has been taken."
1970 — "In Anxiety—Relaxation Rather Than Drowsiness" (Stelazine) Smith Kline & French Laboratories A softer, later-register companion ad — aimed at general/outpatient practice rather than institutional settings — attempting to rebrand a phenothiazine antipsychotic as a gentle, non-sedating anxiolytic. A considerable stretch given the extrapyramidal and other effects disclosed in SKF's own contemporaneous literature.
Undated — "Thorazine can allay the suffering caused by the pain of severe bursitis" Smith, Kline & French Laboratories Genre-bending use of chlorpromazine for a non-psychiatric indication — sold not as pain relief but as "serene detachment" from pain, explicitly quoting clinicians describing it as putting "a curtain between them and their pain." Glamour-shot styling, aimed at general practice, not institutional psychiatry.
Undated — "Now He Can Cope..." / "Now She Can Cope..." (Butisol Sodium) McNeil Laboratories, Fort Washington, PA Matched campaign pair, identical copy block ("daytime sedative for everyday situational stress," 15–30mg t.i.d./q.i.d.), differentiated only by gendered crisis imagery: his version shows office/domestic chaos, hers shows her tied up by a child with string amid scattered toys. Butisol is a barbiturate, not a benzodiazepine — meaningfully more dangerous in overdose and dependence than the near-identical "cope with everyday stress" marketing that benzodiazepines would adopt within a few years. This pair sits at the hinge point of that transition.
1970s — "The Battered Parent Syndrome" (Miltown / Meprobamate) Wallace Pharmaceuticals, Cranbury NJ Peak "invented syndrome" marketing: coins a pop-psychology label for ordinary parental exhaustion, explicitly naming the feminist-adjacent role conflict between education/autonomy and domestic expectation as the causative pathology. Notably candid copy admits Miltown is "no substitute for a week in Bermuda, or for emotional readjustment" but "makes the latter easier" — an unusually open acknowledgment that the drug is a stopgap rather than a fix.
Undated — "You Can't Set Her Free. But You Can Help Her Feel Less Anxious." (Serax / Oxazepam) Wyeth Laboratories, Philadelphia PA The most self-aware ad in the set: explicitly states the drug "cannot change her environment," offering only to relieve anxiety, tension, and irritability so she can better "cope with day-to-day problems." Same domestic-confinement framing as the Butisol and Miltown ads, but stated almost as a selling point rather than something to obscure.
1960s — "When the Patient Lashes Out Against 'Them'" (Thorazine) Smith Kline & French Laboratories The most explicit behavioural-control framing in the SKF set: the giant unblinking eye and fleeing/attacking male figure visually equate psychosis with violence, while the copy sells Thorazine on speed of subduing "assaultive or destructive behavior" before pivoting to its slower-acting antipsychotic effects on delusions and hallucinations. Marked "a reminder advertisement" — trade-journal maintenance copy aimed at physicians already prescribing, not an initial pitch. Sits alongside the "Drug Evaders" and hooded-figure Stelazine ads as part of the same institutional-control cluster: patient as threat to be contained first, treated second.
Undated — "Normal People Don't Need Drugs" Anti-drug PSA, publisher unattributed A distinct genre from the rest of this collection — not pharmaceutical advertising but a prevention-era public health poster, aimed at the illustrated-magazine youth-culture aesthetic of the early 1970s. The line quietly does the same rhetorical work as the pharma ads above, in reverse: it defines "normal" by absence of drug use, implicitly pathologising anyone who doesn't fit that frame — the exact same normal/abnormal boundary-drawing the SKF and McNeil ads relied on to sell prescription stimulants, sedatives, and antipsychotics to "everyday" people. Useful as a counterpoint piece: prescription drugs marketed as the solution to ordinary life, while illicit drugs are marketed against on the premise that "normal" people wouldn't need any chemical help at all.
Through-line Taken together, this set traces a continuous chronological arc: unregulated Victorian-era opiates and cocaine sold direct to consumers → early institutional psychiatric marketing built on compliance and control → mid-century stimulants and barbiturates sold to housewives as a fix for domestic fatigue → 1960s–70s "invented syndrome" and tranquilizer marketing that becomes increasingly candid about treating the symptom of confinement rather than the confinement itself. The target of reassurance shifts throughout — sometimes the physician, sometimes the institution, sometimes, by the end, an open acknowledgment to the patient herself that nothing about her circumstances is going to change.
Home
Help
Search
Login
Register
February 25, 2018, 02:30:14 PM
Need help or a chat ?
